{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:45:23Z","timestamp":1791225923873,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T00:00:00Z","timestamp":1667692800000},"content-version":"vor","delay-in-days":2988,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1111\/jth.12647","type":"journal-article","created":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T23:03:19Z","timestamp":1404860599000},"page":"1480-1487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta\u2010analysis"],"prefix":"10.1016","volume":"12","author":[{"given":"M.","family":"Franchini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mengoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cruciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.12647_bb0010","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta\u2010analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"Suppl","key":"10.1111\/jth.12647_bb0015","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1378\/chest.1412S3","article-title":"Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"2","author":"Guyatt","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.12647_bb0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3109\/07853890.2010.539250","article-title":"Old and new anticoagulant drugs: a minireview","volume":"43","author":"Mannucci","year":"2011","journal-title":"Ann Med"},{"key":"10.1111\/jth.12647_bb0025","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ejim.2012.10.001","article-title":"New anticoagulants for treatment of venous thromboembolism","volume":"23","author":"Franchini","year":"2012","journal-title":"Eur J Intern Med"},{"key":"10.1111\/jth.12647_bb0030","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"key":"10.1111\/jth.12647_bb0035","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1001\/archinte.160.11.1612","article-title":"Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation","volume":"160","author":"Hylek","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1111\/jth.12647_bb0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1503\/cmaj.080171","article-title":"Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta\u2010analysis","volume":"179","author":"Oake","year":"2008","journal-title":"CMAJ"},{"key":"10.1111\/jth.12647_bb0045","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.tips.2009.05.001","article-title":"Genetic and clinical factors relating to warfarin dosing","volume":"30","author":"Jonas","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1111\/jth.12647_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev.med.070808.170037","article-title":"Pharmacogenetics of warfarin","volume":"61","author":"Kamali","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1111\/jth.12647_bb0055","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJMra1010600","article-title":"Genomics and drug response","volume":"364","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12647_bb0060","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa044503","article-title":"Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose","volume":"352","author":"Rieder","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12647_bb0065","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2005-03-1108","article-title":"The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen","volume":"106","author":"Sconce","year":"2005","journal-title":"Blood"},{"key":"10.1111\/jth.12647_bb0070","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2008-01-134247","article-title":"A genome\u2010wide scan for common genetic variants with a large influence on warfarin maintenance dose","volume":"112","author":"Cooper","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.12647_bb0075","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation","volume":"358","author":"Schwarz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12647_bb0080","doi-asserted-by":"crossref","first-page":"e1000433","DOI":"10.1371\/journal.pgen.1000433","article-title":"A genome\u2010wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose","volume":"5","author":"Takeuchi","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1111\/jth.12647_bb0085","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2011-03-345173","article-title":"Prospective evaluation of a pharmacogenetics\u2010guided warfarin loading and maintenance dose regimen for initiation of therapy","volume":"118","author":"Gong","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.12647_bb0090","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.jacc.2010.03.009","article-title":"Warfarin genotyping reduces hospitalization rates results from the MM\u2010WES (Medco\u2010Mayo Warfarin Effectiveness study)","volume":"55","author":"Epstein","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.12647_bb0095","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa0809329","article-title":"Estimation of the warfarin dose with clinical and pharmacogenetic data","volume":"360","author":"Klein","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12647_bb0100","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2009-12-255992","article-title":"Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups","volume":"115","author":"Limdi","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.12647_bb0105","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1182\/blood-2008-04-149070","article-title":"The largest prospective warfarin\u2010treated cohort supports genetic forecasting","volume":"113","author":"Wadelius","year":"2009","journal-title":"Blood"},{"key":"10.1111\/jth.12647_bb0110","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa1311388","article-title":"A randomized trial of genotype\u2010guided dosing of acenocoumarol and phenprocoumon","volume":"369","author":"Verhoef","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12647_bb0115","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa1310669","article-title":"A pharmacogenetic versus a clinical algorithm for warfarin dosing","volume":"369","author":"Kimmel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12647_bb0120","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMoa1311386","article-title":"A randomized trial of genotype\u2010guided dosing of warfarin","volume":"369","author":"Pirmohamed","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.12647_bb0125","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s11606-009-0949-1","article-title":"Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin","volume":"24","author":"Kangelaris","year":"2009","journal-title":"J Gen Intern Med"},{"key":"10.1111\/jth.12647_bb0130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00228-008-0584-5","article-title":"Influence of CYP2C9 genotype on warfarin dose requirements\u2013a systematic review and meta\u2010analysis","volume":"65","author":"Lindh","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/jth.12647_bb0135","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1016\/j.ijcard.2013.07.151","article-title":"Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin\u2010treated patients: a systematic review and meta\u2010analysis","volume":"168","author":"Yang","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1111\/jth.12647_bb0140","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2261-10-18","article-title":"Optimal loading dose for the initiation of warfarin: a systematic review","volume":"10","author":"Heneghan","year":"2010","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1111\/jth.12647_bb0145","first-page":"CD008685","article-title":"Optimal loading dose of warfarin for the initiation of oral anticoagulation","volume":"12","author":"Mahtani","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/jth.12647_bb0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF03256417","article-title":"Genotype\u2010based dosing algorithms for warfarin therapy: data review and recommendations","volume":"15","author":"Johnson","year":"2011","journal-title":"Mol Diagn Ther"},{"key":"10.1111\/jth.12647_bb0155","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/clpt.2008.10","article-title":"Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin","volume":"84","author":"Gage","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jth.12647_bb0160","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bcp.12220","article-title":"Pharmacogenetic\u2010guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon","volume":"77","author":"Verhoef","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl","key":"10.1111\/jth.12647_bb0165","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines","volume":"2","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1111\/jth.12647_bb0170","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non\u2010surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.12647_bb0175","unstructured":"Higgins JPT, Green S (Editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. [updated March 2011]. Available at: www.cochrane.org\/training\/cochrane-handbook."},{"key":"10.1111\/jth.12647_bb0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3121\/cmr.3.3.137","article-title":"A prospective, randomized pilot trial of model\u2010based warfarin dose initiation using CYP2C9 genotype and clinical data","volume":"3","author":"Hillman","year":"2005","journal-title":"Clin Med Res"},{"key":"10.1111\/jth.12647_bb0185","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1161\/CIRCULATIONAHA.107.737312","article-title":"Randomized trial of genotype\u2010guided versus standard warfarin dosing in patients initiating oral anticoagulation","volume":"116","author":"Anderson","year":"2007","journal-title":"Circulation"},{"key":"10.1111\/jth.12647_bb0190","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.clpt.6100316","article-title":"CYP2C9 genotype\u2010guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study","volume":"83","author":"Caraco","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/jth.12647_bb0195","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/GIM.0b013e31820ad77d","article-title":"A randomized controlled trial of genotype\u2010based Coumadin initiation","volume":"13","author":"Burmester","year":"2011","journal-title":"Genet Med"},{"key":"10.1111\/jth.12647_bb0200","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1160\/TH12-03-0159","article-title":"Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation","volume":"108","author":"Borgman","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.12647_bb0205","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2217\/pgs.13.145","article-title":"Impact of genotype\u2010guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial","volume":"14","author":"Jonas","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1111\/jth.12647_bb0210","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11239-007-0104-y","article-title":"Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues","volume":"25","author":"Gage","year":"2008","journal-title":"J Thromb Thrombolysis"},{"key":"10.1111\/jth.12647_bb0215","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12647","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.12647","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622040363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622040363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.12647\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:08:17Z","timestamp":1761534497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622040363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S1538783622040363"],"URL":"https:\/\/doi.org\/10.1111\/jth.12647","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta\u2010analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.12647","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}